US FDA awards Fast Track Designation to paxalisib for glioblastoma

Paxalisib is currently being studied in a Phase II study in patients with newly diagnosed glioblastoma with unmethylated O6-Methylguaninemethyltransferase promotor status who have completed initial radiation with concomitant temozolomide.

Biospace Inc.